Oramed Pharmaceuticals Inc reports results for the quarter ended in September 30 - Earnings Summary

• Oramed Pharmaceuticals Inc ORMP.OQ reported a quarterly adjusted loss of 48 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -8 cents. The mean expectation of two analysts for the quarter was for earnings of one cent per share. Wall Street expected results to range from -2 cents to 3 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Oramed Pharmaceuticals Inc's reported EPS for the quarter was a loss of 48 cents​.

• The company reported a quarterly loss of $19.62 million.

• Oramed Pharmaceuticals Inc shares had fallen by 4.1% this quarter and gained 1.3% so far this year.

FORECAST CHANGES

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

Wall Street's median 12-month price target for Oramed Pharmaceuticals Inc is $3.25

This summary was machine generated from LSEG data November 8 at 04:24 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)